studies

mNSCLC - L1 - PDL1 positive, pembrolizumab alone vs. chemotherapy, meta-analysis of study results

OutcomeTE95% CInkI2ROBPub. bias deaths (OS)detailed resultsKEYNOTE-024 (PDL1>50%), 2016 0.60 [0.41; 0.88] KEYNOTE-042 (PDL1>1%), 2019 0.81 [0.71; 0.93] KEYNOTE-042 (PDL1>20%), 2019 0.77 [0.64; 0.92] KEYNOTE-042 (PDL1>50%), 2019 0.69 [0.56; 0.85] 0.76[0.69; 0.84]KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019, KEYNOTE-042 (PDL1>20%), 2019, KEYNOTE-042 (PDL1>50%), 201944%2,996moderatenot evaluable deaths (OS) (extension)detailed resultsKEYNOTE-024 (PDL1>50%), 2016 0.62 [0.48; 0.81] KEYNOTE-042 (PDL1>1%), 2019 0.80 [0.71; 0.90] KEYNOTE-042 (PDL1>20%), 2019 0.75 [0.64; 0.88] KEYNOTE-042 (PDL1>50%), 2019 0.98 [0.82; 1.18] 0.79[0.68; 0.92]KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019, KEYNOTE-042 (PDL1>20%), 2019, KEYNOTE-042 (PDL1>50%), 2019467%2,996moderatenot evaluable PFS (extension)detailed resultsKEYNOTE-024 (PDL1>50%), 2016 0.50 [0.39; 0.65] KEYNOTE-042 (PDL1>1%), 2019 1.05 [0.93; 1.18] KEYNOTE-042 (PDL1>20%), 2019 0.95 [0.82; 1.10] KEYNOTE-042 (PDL1>50%), 2019 0.85 [0.71; 1.01] 0.82[0.64; 1.06]KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019, KEYNOTE-042 (PDL1>20%), 2019, KEYNOTE-042 (PDL1>50%), 2019489%2,996moderatenot evaluable progression or deaths (PFS)detailed resultsKEYNOTE-024 (PDL1>50%), 2016 0.50 [0.37; 0.68] KEYNOTE-042 (PDL1>1%), 2019 1.07 [0.94; 1.21] KEYNOTE-042 (PDL1>20%), 2019 0.94 [0.80; 1.11] KEYNOTE-042 (PDL1>50%), 2019 0.81 [0.67; 0.98] 0.82[0.64; 1.06]KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019, KEYNOTE-042 (PDL1>20%), 2019, KEYNOTE-042 (PDL1>50%), 2019487%2,996moderatenot evaluable objective responses (ORR)detailed resultsKEYNOTE-024 (PDL1>50%), 2016 2.11 [1.31; 3.39] KEYNOTE-042 (PDL1>1%), 2019 1.04 [0.81; 1.33] KEYNOTE-042 (PDL1>20%), 2019 1.24 [0.92; 1.66] KEYNOTE-042 (PDL1>50%), 2019 1.39 [0.99; 1.94] 1.32[1.03; 1.69]KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019, KEYNOTE-042 (PDL1>20%), 2019, KEYNOTE-042 (PDL1>50%), 2019458%2,996moderatenot evaluable objective responses (ORR) (extension)detailed resultsKEYNOTE-024 (PDL1>50%), 2016 1.89 [1.19; 3.02] KEYNOTE-042 (PDL1>1%), 2019 1.03 [0.81; 1.32] KEYNOTE-042 (PDL1>20%), 2019 1.21 [0.90; 1.62] KEYNOTE-042 (PDL1>50%), 2019 1.35 [0.96; 1.88] 1.26[1.02; 1.57]KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019, KEYNOTE-042 (PDL1>20%), 2019, KEYNOTE-042 (PDL1>50%), 2019445%2,996moderatenot evaluable STRAE (any grade)detailed resultsKEYNOTE-024 (PDL1>50%), 2016 1.05 [0.60; 1.82] 1.05[0.60; 1.82]KEYNOTE-024 (PDL1>50%), 201610%304NAnot evaluable STRAE (grade 3-4)detailed resultsKEYNOTE-024 (PDL1>50%), 2016 0.97 [0.55; 1.72] 0.97[0.55; 1.72]KEYNOTE-024 (PDL1>50%), 201610%304NAnot evaluable TRAE (any grade)detailed resultsKEYNOTE-024 (PDL1>50%), 2016 0.31 [0.16; 0.58] KEYNOTE-042 (PDL1>1%), 2019 0.19 [0.14; 0.26] 0.22[0.14; 0.34]KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019244%1,555moderatenot evaluable TRAE (grade 3-4)detailed resultsKEYNOTE-024 (PDL1>50%), 2016 0.32 [0.20; 0.51] KEYNOTE-042 (PDL1>1%), 2019 0.30 [0.23; 0.39] 0.30[0.24; 0.38]KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 201920%1,555moderatenot evaluable TRAE leading to death (grade 5)detailed resultsKEYNOTE-024 (PDL1>50%), 2016 0.32 [0.03; 3.11] KEYNOTE-042 (PDL1>1%), 2019 0.90 [0.42; 1.92] 0.81[0.39; 1.66]KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 201920%1,555moderatenot evaluable TRAE leading to discontinuation (any grade)detailed resultsKEYNOTE-024 (PDL1>50%), 2016 0.64 [0.29; 1.44] KEYNOTE-042 (PDL1>1%), 2019 0.95 [0.64; 1.39] 0.88[0.62; 1.24]KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 201920%1,555moderatenot evaluable TRAE leading to discontinuation (grade 3-4)detailed resultsKEYNOTE-024 (PDL1>50%), 2016 0.86 [0.32; 2.29] KEYNOTE-042 (PDL1>1%), 2019 1.09 [0.71; 1.66] 1.05[0.71; 1.55]KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 201920%1,555moderatenot evaluable Adrenal insufficiency TRAE (grade 3-4)detailed resultsKEYNOTE-042 (PDL1>1%), 2019 3.88 [0.17; 86.15] 3.88[0.17; 86.15]KEYNOTE-042 (PDL1>1%), 201910%1,251NAnot evaluable Alopecia TRAE (grade 3-4)detailed resultsKEYNOTE-042 (PDL1>1%), 2019 0.07 [0.00; 1.21] 0.07[0.00; 1.21]KEYNOTE-042 (PDL1>1%), 201910%1,251NAnot evaluable Anaemia TRAE (grade 3-4)detailed resultsKEYNOTE-024 (PDL1>50%), 2016 0.08 [0.02; 0.28] KEYNOTE-042 (PDL1>1%), 2019 0.04 [0.02; 0.12] 0.06[0.03; 0.12]KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 201920%1,555moderatenot evaluable Arthralgia TRAE (grade 3-4)detailed resultsKEYNOTE-042 (PDL1>1%), 2019 0.97 [0.02; 48.81] 0.97[0.02; 48.81]KEYNOTE-042 (PDL1>1%), 201910%1,251NAnot evaluable Asthenia TRAE (grade 3-4)detailed resultsKEYNOTE-042 (PDL1>1%), 2019 0.29 [0.08; 1.05] 0.29[0.08; 1.05]KEYNOTE-042 (PDL1>1%), 201910%1,251NAnot evaluable Blood creatinine increased TRAE (grade 3-4)detailed resultsKEYNOTE-024 (PDL1>50%), 2016 0.49 [0.02; 14.58] 0.49[0.02; 14.58]KEYNOTE-024 (PDL1>50%), 201610%304NAnot evaluable Colitis TRAE (grade 3-4)detailed resultsKEYNOTE-024 (PDL1>50%), 2016 3.93 [0.18; 87.97] KEYNOTE-042 (PDL1>1%), 2019 3.89 [0.43; 34.87] 3.90[0.65; 23.43]KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 201920%1,555moderatenot evaluable Constipation TRAE (grade 3-4)detailed resultsKEYNOTE-024 (PDL1>50%), 2016 0.97 [0.02; 49.41] KEYNOTE-042 (PDL1>1%), 2019 0.97 [0.02; 48.81] 0.97[0.06; 15.56]KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 201920%1,555moderatenot evaluable Decreased appetite TRAE (grade 3-4)detailed resultsKEYNOTE-024 (PDL1>50%), 2016 0.12 [0.01; 2.27] KEYNOTE-042 (PDL1>1%), 2019 0.53 [0.18; 1.60] 0.44[0.16; 1.24]KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 201920%1,555moderatenot evaluable Diabetes TRAE (grade 3-4)detailed resultsKEYNOTE-024 (PDL1>50%), 2016 1.95 [0.07; 58.69] 1.95[0.07; 58.69]KEYNOTE-024 (PDL1>50%), 201610%304NAnot evaluable Diarrhoea TRAE (grade 3-4)detailed resultsKEYNOTE-024 (PDL1>50%), 2016 3.00 [0.60; 15.11] KEYNOTE-042 (PDL1>1%), 2019 4.87 [0.57; 41.77] 3.57[0.98; 13.00]KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 201920%1,555moderatenot evaluable Dysgeusia TRAE (grade 3-4)detailed resultsKEYNOTE-024 (PDL1>50%), 2016 0.97 [0.02; 49.41] 0.97[0.02; 49.41]KEYNOTE-024 (PDL1>50%), 201610%304NAnot evaluable Fatigue TRAE (grade 3-4)detailed resultsKEYNOTE-024 (PDL1>50%), 2016 0.38 [0.07; 2.00] KEYNOTE-042 (PDL1>1%), 2019 0.36 [0.09; 1.36] 0.37[0.13; 1.04]KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 201920%1,555moderatenot evaluable Hepatitis TRAE (grade 3-4)detailed resultsKEYNOTE-042 (PDL1>1%), 2019 13.68 [0.77; 241.54] 13.68[0.77; 241.54]KEYNOTE-042 (PDL1>1%), 201910%1,251NAnot evaluable Hyperthyroidism TRAE (grade 3-4)detailed resultsKEYNOTE-024 (PDL1>50%), 2016 0.97 [0.02; 49.41] KEYNOTE-042 (PDL1>1%), 2019 1.94 [0.06; 57.80] 1.44[0.11; 18.83]KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 201920%1,555moderatenot evaluable Hypophysitis TRAE (grade 3-4)detailed resultsKEYNOTE-024 (PDL1>50%), 2016 1.95 [0.07; 58.69] KEYNOTE-042 (PDL1>1%), 2019 5.82 [0.29; 116.52] 3.62[0.38; 34.25]KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 201920%1,555moderatenot evaluable Hypothyroidism TRAE (grade 3-4)detailed resultsKEYNOTE-024 (PDL1>50%), 2016 0.97 [0.02; 49.41] KEYNOTE-042 (PDL1>1%), 2019 1.94 [0.06; 57.80] 1.44[0.11; 18.83]KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 201920%1,555moderatenot evaluable Increase AST TRAE (grade 3-4)detailed resultsKEYNOTE-042 (PDL1>1%), 2019 1.94 [0.35; 10.63] 1.94[0.35; 10.63]KEYNOTE-042 (PDL1>1%), 201910%1,251NAnot evaluable Increased ALT TRAE (grade 3-4)detailed resultsKEYNOTE-042 (PDL1>1%), 2019 1.75 [0.58; 5.26] 1.75[0.58; 5.26]KEYNOTE-042 (PDL1>1%), 201910%1,251NAnot evaluable Infusion-related reactions TRAE (grade 3-4)detailed resultsKEYNOTE-024 (PDL1>50%), 2016 0.97 [0.02; 49.41] KEYNOTE-042 (PDL1>1%), 2019 0.16 [0.02; 1.33] 0.24[0.04; 1.55]KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 201920%1,555moderatenot evaluable Leucopenia TRAE (grade 3-4)detailed resultsKEYNOTE-042 (PDL1>1%), 2019 0.05 [0.00; 0.82] 0.05[0.00; 0.82]KEYNOTE-042 (PDL1>1%), 201910%1,251NAnot evaluable Myalgia TRAE (grade 3-4)detailed resultsKEYNOTE-042 (PDL1>1%), 2019 1.94 [0.06; 57.80] 1.94[0.06; 57.80]KEYNOTE-042 (PDL1>1%), 201910%1,251NAnot evaluable Myocarditis TRAE (grade 3-4)detailed resultsKEYNOTE-042 (PDL1>1%), 2019 1.94 [0.06; 57.80] 1.94[0.06; 57.80]KEYNOTE-042 (PDL1>1%), 201910%1,251NAnot evaluable Myositis TRAE (grade 3-4)detailed resultsKEYNOTE-024 (PDL1>50%), 2016 0.97 [0.02; 49.41] 0.97[0.02; 49.41]KEYNOTE-024 (PDL1>50%), 201610%304NAnot evaluable Nausea TRAE (grade 3-4)detailed resultsKEYNOTE-024 (PDL1>50%), 2016 0.16 [0.01; 3.21] KEYNOTE-042 (PDL1>1%), 2019 0.07 [0.00; 1.21] 0.10[0.01; 0.82]KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 201920%1,555moderatenot evaluable Nephritis TRAE (grade 3-4)detailed resultsKEYNOTE-024 (PDL1>50%), 2016 1.95 [0.07; 58.69] KEYNOTE-042 (PDL1>1%), 2019 1.94 [0.06; 57.80] 1.94[0.18; 21.52]KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 201920%1,555moderatenot evaluable Neutropenia TRAE (grade 3-4)detailed resultsKEYNOTE-024 (PDL1>50%), 2016 0.02 [0.00; 0.35] KEYNOTE-042 (PDL1>1%), 2019 0.02 [0.00; 0.14] 0.02[0.00; 0.10]KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 201920%1,555moderatenot evaluable Pancreatitis TRAE (grade 3-4)detailed resultsKEYNOTE-024 (PDL1>50%), 2016 1.95 [0.07; 58.69] KEYNOTE-042 (PDL1>1%), 2019 0.97 [0.02; 48.81] 1.44[0.11; 18.87]KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 201920%1,555moderatenot evaluable Peripheral neuropathy TRAE (grade 3-4)detailed resultsKEYNOTE-042 (PDL1>1%), 2019 0.10 [0.01; 1.76] 0.10[0.01; 1.76]KEYNOTE-042 (PDL1>1%), 201910%1,251NAnot evaluable Peripheral sensory neuropathy TRAE (grade 3-4)detailed resultsKEYNOTE-042 (PDL1>1%), 2019 0.08 [0.00; 1.43] 0.08[0.00; 1.43]KEYNOTE-042 (PDL1>1%), 201910%1,251NAnot evaluable Pneumonitis TRAE (grade 3-4)detailed resultsKEYNOTE-024 (PDL1>50%), 2016 3.97 [0.44; 35.97] KEYNOTE-042 (PDL1>1%), 2019 20.97 [2.81; 156.36] 9.73[1.92; 49.42]KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019216%1,555moderatenot evaluable Pruritus TRAE (grade 3-4)detailed resultsKEYNOTE-042 (PDL1>1%), 2019 3.88 [0.17; 86.15] 3.88[0.17; 86.15]KEYNOTE-042 (PDL1>1%), 201910%1,251NAnot evaluable Pyrexia TRAE (grade 3-4)detailed resultsKEYNOTE-024 (PDL1>50%), 2016 0.97 [0.02; 49.41] 0.97[0.02; 49.41]KEYNOTE-024 (PDL1>50%), 201610%304NAnot evaluable Rash TRAE (grade 3-4)detailed resultsKEYNOTE-042 (PDL1>1%), 2019 5.82 [0.29; 116.52] 5.82[0.29; 116.52]KEYNOTE-042 (PDL1>1%), 201910%1,251NAnot evaluable Severe skin reaction TRAE (grade 3-4)detailed resultsKEYNOTE-024 (PDL1>50%), 2016 12.12 [0.67; 218.98] KEYNOTE-042 (PDL1>1%), 2019 10.81 [1.39; 83.96] 11.23[2.11; 59.83]KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 201920%1,555moderatenot evaluable Stomatitis TRAE (grade 3-4)detailed resultsKEYNOTE-024 (PDL1>50%), 2016 0.24 [0.01; 5.39] KEYNOTE-042 (PDL1>1%), 2019 0.97 [0.02; 48.81] 0.41[0.04; 4.70]KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 201920%1,555moderatenot evaluable Thrombocytopenia TRAE (grade 3-4)detailed resultsKEYNOTE-024 (PDL1>50%), 2016 0.06 [0.00; 1.02] KEYNOTE-042 (PDL1>1%), 2019 0.10 [0.01; 0.75] 0.08[0.02; 0.43]KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 201920%1,555moderatenot evaluable Thyroiditis TRAE (grade 3-4)detailed resultsKEYNOTE-024 (PDL1>50%), 2016 0.97 [0.02; 49.41] KEYNOTE-042 (PDL1>1%), 2019 0.97 [0.02; 48.81] 0.97[0.06; 15.56]KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 201920%1,555moderatenot evaluable Vomiting TRAE (grade 3-4)detailed resultsKEYNOTE-024 (PDL1>50%), 2016 0.97 [0.06; 15.71] KEYNOTE-042 (PDL1>1%), 2019 0.24 [0.01; 5.36] 0.52[0.07; 4.14]KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 201920%1,555moderatenot evaluable0.020.01.0relative treatment effectwww.metaEvidence.org2024-05-29 17:09 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 171 - treatments: 359,575,577,576,869

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons